Skip to content Skip to footer
Subscribe Now
Eli Lilly
NEWS

Eli Lilly Reports the US FDA’s Approval of Kisunla (donanemab-azbt) to Treat Early Symptomatic Alzheimer’s Disease 

Shots:   The approval of Kisunla (350mg/20mL, IV, QM) for early symptomatic Alzheimer's disease was based on P-III (TRAILBLAZER-ALZ 2) study. Coverage & reimbursement is available through National Coverage Determination with Coverage with Evidence Development  The P-III (TRAILBLAZER-ALZ 2) trial assessed Kisunla vs PBO in patients (n=1,736) with early symptomatic AD (MCI or mild dementia) &…
July 2, 2024

Read more

VIEWPOINTS_Michael Irizarry1_2023
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

Shots: Michael spoke about the P-III Clarity AD study evaluating Leqembi (lecanemab) for the treatment of mild cognitive impairment due to Alzheimer’s disease presented at CTAD 2022 He also talked about Eisai’s collaboration with Biogen for the co-commercialization and co-promotion of Lecanemab The interview gives an understanding of how Biogen develops and delivers innovative therapies…
July 4, 2023

Read more

VIEWPOINTS_Gregory Bell_2023
VIEWPOINTS

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Shots: Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease He also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…
May 30, 2023

Read more

VIEWPOINTS_Craig Thompson_2023
VIEWPOINTS

Craig Thompson, CEO of Cerevance Shares Insights from the Preclinical Data Presented at the Society for Neuroscience (SFN) 2022

Shots:   Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease  He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…
March 20, 2023

Read more

VIEWPOINTS_Jason-Winnike_2023
VIEWPOINTS

Jason Winnike, Study Director at Metabolon Shares Insights from the Launch of its Oxysterol Targeted Panel

Shots: Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features  He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer  The interview gives a profound understanding…
March 6, 2023

Read more

Viewpoints_Michael Irizarry
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAIC

Shots: Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC) Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemab The interview gives an understanding of  Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…
December 14, 2022

Read more